- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-05231023, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 5
- States / cities
- Chula Vista, California • Miami, Florida • South Miami, Florida + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)) Clear all
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
- Drug
- Lead sponsor
- Epitopoietic Research Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • Boston, Massachusetts
- Conditions
- Acute Lung Injury, ALI, COVID-19
- Interventions
- RLS-0071 10 mg/kg, RLS-0071 40 mg/kg, Placebo
- Drug
- Lead sponsor
- ReAlta Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Albiglutide 50 mg, Placebo, CCK (Kinevac)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Placebo, 100 mg PF-05231023
- Other · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Orlando, Florida
- Conditions
- Diabetes Melliuts, Type 2
- Interventions
- Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
- Other · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 17
- States / cities
- Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more